UPDATE: Goldman Maintains Buy On Incyte, Lowers Target To $107, Keeps On Americas Conviction List Notes 'Ph3 GRAVITAS-301 fails; Looking to atopic dermatitis in 1H20'

Benzinga · 01/03/2020 15:37